Journal
BRITISH JOURNAL OF CANCER
Volume 100, Issue 3, Pages 431-435Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604891
Keywords
melanoma; targeted therapy; BRAF; PI3K; mTOR; PTEN; chemotherapy
Categories
Ask authors/readers for more resources
The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available